Published online May 26, 2022. doi: 10.12998/wjcc.v10.i15.4810
Peer-review started: January 10, 2022
First decision: February 14, 2022
Revised: February 28, 2022
Accepted: March 26, 2022
Article in press: March 26, 2022
Published online: May 26, 2022
The thoracoscopic assisted technique has the characteristics of small incision, clear surgical field and high safety.
This study investigated the effect of thoracoscopic tricuspid valvuloplasty in patients with tricuspid valve disease.
Whether thoracic assistive technology significantly reduced the duration of cardiopulmonary bypass, aorta blocking time, endotracheal intubation time, operation time, postoperative C-reactive protein, white blood cell count, cardiac troponin T, creatine kinase isoenzyme, creatine kinase and the incidence of adverse events between the two groups and traditional surgery.
A total of 41 patients with tricuspid valve disease underwent traditional thoracotomy treatment were included. Patients in the study group underwent thoracoscopic tricuspid valvuloplasty and were intubated with a 35 F double-lumen endotracheal tube for one-lung ventilation. Patients in the control group underwent a traditional thoracotomy. From the medical records, we collected information on operational conditions, including the duration of extracorporeal circulation, aorta blocking, endotracheal intubation, and surgery.
The duration of extracorporeal circulation, aortic occlusion, endotracheal intubation, and hospital stay was shorter in the study group than in the control group. The incidence of adverse events in the study group was significantly lower than that in the control group.
Thoracoscopic tricuspid valvuloplasty can achieve good results in treating patients with tricuspid valve disease, reduce the risk of adverse events, and promote the rapid recovery of patients.
We will expand the scope of the clinical study and increase the sample size to further explore and confirm whether the results of the study have a wide range of effectiveness.